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Abstract 
The phenothiazinium derivative toluidine blue O (TBO) is widely employed as a 
photoantimicrobial agent in clinical trialling, particularly in dentistry.  However, its activity 
against a range of pathogenic microbial species is not significantly different to that of the 
standard photoantimicrobial methylene blue.  In the current study, derivatives of TBO with 
varying hydrocarbon substitution in chromophore position 2 were synthesised via the 
established anilinethiosulphonic route, using the mild oxidant silver(II) carbonate to allow 
substituent preservation. 
The resulting series of analogues demonstrated the expected increases in visible absorption 
wavelength and lipophilicity with increasing hydrocarbon content, as well as decreased 
aggregation for derivatives with bulkier substituents, and all produced singlet oxygen on 
illumination in vitro.  Screening against a range of bacterial and fungal pathogens relevant to 
infection control showed remarkable increases in activity relative to the parent compound, 
particularly against the clinically important Gram-negative bacterium Pseudomonas 
aeruginosa.  In addition, in order to demonstrate clinical relevance, the photoactivities of 
the new derivatives against microbial targets were compared to conventional antibacterial 
and antifungal drugs, as well as biocides commonly used for local disinfection.  Activity here 
was also generally greater than that of the conventional agents used for comparison, 
considerably so relative to the local disinfectant agents. 
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1. Introduction 
  
Toluidine blue O (tolonium chloride, TBO, Figure 1) is a phenothiazinium derivative related 
to methylene blue (MB, Figure 1).  It has been used widely in the biological arena as a stain 
in the pathology of both cancer and microbial disease [1,2].  More recently TBO has been 
widely examined as a photoantimicrobial agent aimed at oral disinfection [3,4], and is a lead 
compound in azine photosensitiser research and development [5]. 
 
 
 
 
Figure 1.  Accepted structures for toluidine blue O and methylene blue cations. 
 
Where comparative testing of the photoantimicrobial efficacies of MB and TBO have been 
carried out, little overall difference has been reported [6].  However, as the principal lead 
compound for photoantimicrobial research, MB has a significantly fuller pedigree in terms 
of the range of bacterial, fungal, viral and protozoal challenges reported [7].  Logically, both 
are established to interact with anionic groups at the external surfaces of the microbial 
target, e.g. with lipoteichoic acids [8], and to displace stabilising metal cations in membrane 
structures [9]. 
 
The use of TBO in biological staining often utilises the property of metachromasia.  This is 
exhibited as a change in colour of the stained tissue due to the significant aggregation of the 
highly planar, substituted phenothiazinium cation [10].  As the chromophore concerned is 
established as a planar moiety, this infers that neither the auxochromic dimethylamino- or 
amino- groups, nor the methyl at position 2 of the ring system cause any deviation from 
this.  Aggregates can be observed in the visible spectrum of aqueous TBO – and similarly for 
other phenothiazinium cations - as a broad shoulder to lower wavelengths extending from 
the max [6]. 
 
As part of the ongoing programme of photosensitiser discovery, improved derivatives of 
toluidine blue were sought – particularly for photoantimicrobial analoguing - by variation of 
the group at C-2 of the chromophore.  Previous work has demonstrated that the use of 
increased chromophore methylation leads to greater photoantimicrobial activity in 
derivatives of both methylene blue and azure A [11,12]. 
 
 
2. Materials & Methods 
 
2.1 Synthesis 
 
Substituted anilines, p-phenylenediamine derivatives, silver carbonate (5% w/w on celite) 
and solvents were purchased from Sigma-Aldrich UK, and used without further purification.  
Photophysical characterisation of the products was carried out using a Hewlett Packard 
8452A diode array spectrophotometer.  This was also used for the determination of singlet 
oxygen yield and of lipophilicity.  Accurate molecular ion masses (m/z) for the derivatives 
were obtained using a Micromass LCT TOF mass spectrometer. 
 
 
2-Amino-5-dimethylaminophenylthiosulphonic acid 
N,N-Dimethyl-p-phenylenediamine sulphate (130 mmol) was added to a mechanically 
stirred solution of aluminium sulfate octadecahydrate/water (43.6 g, 65 mmol/100 ml). To 
this was added a solution of sodium thiosulfate in water (22.0 g, 139 mmol/80 ml) followed 
by zinc chloride in water (8.8 g, 63 mmol/12 ml). The reaction solution was cooled to 0 °C 
and aqueous potassium dichromate (5.0 g, 17 mmol in 20 ml water) was added dropwise 
over a 30 minute period.  Following this addition, the mixture was allowed to stir for 2 
hours. During the last 30 minutes the temperature was allowed to rise to 10 °C causing the 
formation of a viscous precipitate. This was isolated by filtration and washed with water 
followed by acetone.  Yield=15.87 g (49%), m.p. 190 °C (dec.) 
 
 
2-Alkyl-3-amino-7-dimethylaminophenothiazinium derivatives 
2-Amino-5-dimethylaminophenylthiosulphonic acid (4 mmol) and 2-alkylaniline (5 mmol) 
were refluxed in 120 ml methanol and silver carbonate on celite (5 g, 50% w/w) was added 
slowly over 0.5 h. The reaction mixture was refluxed for a further hour, filtered through a 
celite pad and the filtrates evaporated. The residue was extracted with dichloromethane 
and purified by column chromatography on silica. 
 
3-Amino-7-dimethylamino-2-methylphenothiazinium hydrogensulphate (toluidine blue O, 
1a) 
Prepared as above from 2-amino-5-dimethylaminophenylthiosulphonic acid and 2-
methylaniline.  Blue-black powder, yield = 460 mg, 31%; m/s C15H16N3S requires 270.11, 
found 270.11; max (MeOH) 629 nm. 
 
3-Amino-7-(dimethylamino)-2-ethylphenothiazinium hydrogensulphate (1b) 
 
From 2-amino-5-dimethylaminobenzenethiosulphonic acid and 2-ethylaniline as violet-blue 
crystals, yield = 273 mg, 18%; m/z, C16H18N3S requires 284.40, found 284.42; max (MeOH) 
634 nm. 
 
3-Amino-7-(dimethylamino)-2-n-propylphenothiazinium hydrogensulphate (1c) 
 
From 2-amino-5-dimethylaminobenzenethiosulphonic acid and 2-n-propylaniline as blue-
black powder, yield = 302 mg, 19%; m/z, C17H20N3S requires 298.43, found 298.40; max 
(MeOH) 636 nm. 
 
3-Amino-2-tert-butyl-7-(dimethylamino)phenothiazinium hydrogensulphate (1d) 
 
From 2-amino-5-dimethylaminobenzenethiosulphonic acid and 2-tert-butylaniline as black 
powder, yield = 487 mg, 30%; m/z, C18H22N3S requires 312.45, found 312.41; max (MeOH) 
637 nm. 
 
3-Amino-7-(dimethylamino)-2-phenylphenothiazinium hydrogensulphate (1e) 
 
From 2-amino-5-dimethylaminobenzenethiosulphonic acid and 2-aminobiphenyl as dark 
blue powder, yield = 455 mg, 26%; m/z, C20H18N3S requires 332.44, found 332.41; max 
(MeOH) 639 nm. 
 
 
2.2 Singlet oxygen testing 
 
Singlet oxygen production by the photosensitisers was assayed as in previous work [13], 
using the decolourisation of 2,3,4,5-tetraphenylcyclopentadienone (TPCPD) in 
dichloromethane.  Thus the decrease in absorption of TPCPD at 500 nm was monitored 
spectrophotometrically with time, using methylene blue as a standard photosensitiser.  By 
assuming that the decrease in absorption of TPCPD at 500 nm is directly proportional to its 
reaction with singlet oxygen, the time for a 50% decrease in absorption caused by each of 
the toluidine blue derivatives under identical conditions (t½TBD) thus gives a measure of its 
photosensitising efficiency.  Thus, if the time for the DPIBF absorption to decrease by 50% 
due to TBO photosensitisation is t½TBO, relative singlet oxygen yields for the derivatives are 
given by: 
 
 
 
i.e. the lower the t1/2 value for the derivative, the greater its 
1O2 yield. 
 
 
2.3 Lipophilicity (LogP) 
 
The lipophilicities of the photosensitisers were calculated in terms of log P, the logarithm of 
their partition coefficients between phosphate-buffered saline and 1-octanol.  The data 
were calculated using the standard spectrophotometric method [14] based on the 
relationship: 
 
 
 
where A and A1 are the absorption intensities before and after partitioning respectively and 
Vw and Vo are the respective volumes of the aqueous and 1-octanol phases. Determinations 
were repeated three times. 
 
 
2.4 Antimicrobial Screening/Comparison 
 
The photobactericidal efficacies of the derivatives in addition to that of the known 
photosensitiser methylene blue were measured against both Gram positive Staphylococcus 
aureus (NCTC 6571) and Enterococcus faecalis (NCIMB 13280) and Gram negative 
Escherichia coli (NCTC 10418), Proteus mirabilis (NCIMB 5887) and a clinical strain of 
Pseudomonas aeruginosa (P. aeruginosa) bacteria (courtesy of the Clatterbridge Hospital, 
Bebington, UK) .  Strains were grown in Mueller-Hinton Broth and then diluted to a 
concentration of 106 colony-forming units/ml.  Aliquots of the strains were then incubated 
for 1 hour at 37 C in microtitre trays with various concentrations of photosensitiser in 
doubling dilutions from 100 M, with zero photosensitiser concentrations in each case for 
control purposes.  The trays were then either illuminated for twenty minutes using an array 
of light-emitting diodes (660 nm) giving a light dose of 6.2 J cm-2 or alternatively foil-covered 
to provide dark controls.  From each well showing an inhibition of growth of the micro-
organism, 1 l was sub-cultured on nutrient agar, using the Miles-Misra method, and 
incubated for 18 hours at 37 C.  The minimum bactericidal concentrations were then 
determined as the lowest concentration for each photosensitiser giving no bacterial growth. 
 
The standard antibacterial agent levofloxacin and several disinfectants (chlorhexidine 
digluconate, cetyltrimethylammonium bromide, benzalkonium chloride and  
Triclosan, purchased from Sigma-Aldrich, Gillingham UK) were screened for activity in the 
same way as above. 
 
Antifungal screening was carried out similarly against the yeast Candida albicans (NCPF 
8179), using Sabouraud broth and agar.  The standard antifungal agent fluconazole (Sigma-
Aldrich, Gillingham, UK) was included in this test for comparison. 
 
 
3. Results & Discussion 
 
3.1 Photosensitisers 
 
Toluidine blue and its analogues were synthesised in straightforward manner, in low-
moderate yields (around 30%), and normally requiring purification by column 
chromatography. 
Given the importance of photosensitiser action wavelength in avoiding endogenous light 
absorption – typically by blood – the derivatives exhibited the expected increases in max 
with electron release of the groups added at C-2 of the phenothiazinium chromophore 
(Table 1). 
 
 
 
 
R2 max 
(nm, MeOH) 
1O2 yield* LogP 
Me 629 1.00 -0.20† 
Et 634 1.49 -0.46 
n-Pr 636 1.24 +0.29 
t-Bu 637 1.79 +0.84 
Ph 639 1.87 +0.63 
 
Table 1.  Relevant properties for the toluidine blue derivatives (* relative to toluidine blue; 
†Lit. -0.21[15]) 
 Similarly, the LogP values of the derivatives increased, as expected, with hydrocarbon 
content (Table 1), with most resulting compounds being in the range normally considered to 
be amphiphilic, and all retaining water solubility. 
 
All derivatives were shown to produce singlet oxygen in reasonable yields in the in vitro test 
(Table 1), although this may not reflect activity against target cells, since this is dependent 
on the eventual cellular environment / biomolecular binding of the photosensitiser. 
 
Inspection of the visible spectra of the alkyl toluidine blue derivatives revealed a lessening 
of the lower-wavelength shoulder to the main peak absorption in the red region with 
increasing alkyl group size at C-2 (TBO and the t-butyl derivative shown in Figure 2).  As 
noted, the max was shifted with increasing hydrocarbon group size, via hyperconjugation, as 
expected.  The decreased shoulder with increased alkyl size indicates a drop in 
aggregational behaviour, logically due to the difficulty in packing caused by the extra 
asymmetrical volume incurred.  This volume change is demonstrated in the energy-
minimised, space-filling models of TBO and its 2-tert-butyl derivative in Figure 3.  However, 
the 2-phenyl derivative demonstrated intermediate aggregation, with the shoulder more 
emphasised (Figure 2).  While the phenyl moiety is relatively large, even compared to tert-
butyl, it is assumed that it adopts a coplanar orientation with the phenothiazinium 
chromophore at higher concentrations, allowing aggregation to occur. 
 
 
 
 
Figure 2.  Aqueous visible absorption by TBO (black), t-BuTB (grey dashes) and PhTB (mid-
grey), showing variation in the aggregational, lower wavelength, shoulder 
(photoantimicrobial concentration approx. 15 M). 
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Figure 3. Increased asymmetric molecular volume due to 2-tert-butyl group substitution (b) 
compared to TBO (a) (energy minimised structures using ChemDraw 3D software). 
 
3.2 Antimicrobial efficacy 
 
Photoantimicrobial activity among the derivatives was first screened against the standard 
Gram-positive/Gram-negative bacteria S. aureus and E. coli, respectively, and the yeast 
Candida albicans.  A subset were further screened against a range of clinically relevant 
pathogens, the 2-phenyl analogue being excluded due to solubility problems.  The 
derivatives generally exhibited significant improvements on the lead compound, toluidine 
blue, but also on the principally-used photoantimicrobial compound, methylene blue (Table 
2).  In addition, the activity profile was not decreased against Gram-negative species, as has 
been widely reported in the literature for both lead compounds [16].  Such broad-spectrum 
potential is important given the polymicrobial nature of many clinical infections and would 
aid in local ‘photoempirical’ administration for wounds at the clinical triage stage, this being 
a logical application of photoantimicrobials, allowing conservation of conventional systemic 
drugs.  The efficacy of TBO against bacteria in biofilms [17] and in trialling against suitable 
conditions/presentations in vivo, such as onychomycosis [18] and osteomyelitis [19] is also 
encouraging, both for clinical involvement outside dentistry and in the search for improved 
photoantimicrobial agents. 
  
(a) (b) 
 
R2   MBC (M)     
 S. aureus 
(Gram +) 
E. coli 
(-) 
Enterococcus 
faecalis 
(+) 
Proteus 
mirabilis 
(-) 
P. 
 acnes 
(+) 
P. 
 aeruginosa 
(-) 
Candida 
albicans 
Me 7.36 7.36 7.36 14.71 0.78 7.36 12.5 
Et 3.13 1.47 1.35 5.50 - 3.13 3.13 
n-Pr 3.13 1.32 0.33 5.70 0.39 0.78 0.78 
t-Bu 3.13 3.13 0.33 3.13 0.78 0.39 3.13 
Ph 3.13 3.13 - - - - 0.78 
        
MB 25 25 100 0.20 50 25 3.13  
Levo 6.26 3.13 100 3.13 - 25 - 
Fluc - - - - - - 25 
BPO - - - - 56 - - 
 
Table 2. Photoantimicrobial activity for TBO analogues (MBC – minimum bactericidal 
concentration; MB – methylene blue; Levo – levofloxacin, standard antibacterial; Fluc – 
fluconazole, standard antifungal; BPO – benzoyl peroxide, standard topical acne treatment). 
 
Given that interaction between the target organism and the photoantimicrobial agent is 
essential to successful cell kill, the improvements in activity among the derivatives may be 
due both to the increased lipophilicity and decreased propensity for aggregation noted 
above (Table 1 / Figure 2). 
 
Comparators were included in the study to provide some indication of clinical relevance and 
potential and, here again, the new derivatives generally exhibited similar or increased 
activities on illumination - for example, in comparison to the fluoroquinolone derivative 
levofloxacin against Enterococcus faecalis and Pseudomonas aeruginosa, or the imidazole 
antifungal fluconazole against Candida albicans (Table 2).  Similarly, those derivatives 
screened against Propionibacterium acnes (P. acnes) were much more effective (MBC < 1 
M) than the standard acne medication benzoyl peroxide (MBC = 56 M). 
 
 
  
  
Figure 4.  Photobactericidal efficacies vs. standard bacteria of a range of photosensitisers 
measured against standard disinfectants (abbreviations as above, except: CX – chlorhexidine 
digluconate; CTAB – cetyltrimethylammonium bromide; BAC – benzalkonium chloride; Tric – 
triclosan). 
 
Given the potential utility of these agents in local disinfection, testing was also carried out 
against standard topical disinfectants (Figure 4), once again demonstrating the high 
comparative efficacies of the derivatives.  Since three of the topical agents tested were of 
the quaternary cationic class (chlorhexidine digluconate, cetyl trimethylammonium bromide 
and benzalkonium chloride), it is reasonable to suppose that similar areas of the target cells 
– regions containing anionic groups in the cell wall/outer membrane for Gram-positive and 
Gram-negative bacteria respectively - were attacked both by these and the 
photoantimicrobials, but that reactive oxygen generation by the latter ensured rapid 
chemical oxidation of such regions, rather than merely physical interruption in the case of 
the disinfectant agents. 
 
 
4. Conclusions 
 
The established phenothiazinium dyes, having suitable light absorption and photosensitising 
profiles, have been investigated throughout much of the renaissance of research into the 
photodynamic therapy of cancer and photoantimicrobial action [20].  Lead compounds such 
as toluidine blue are structurally simple with relatively straightforward syntheses, allowing 
facile analogue production. 
MB has been reported to produce more singlet oxygen than TBO in various formulations in 
vitro [21], thus the improved performance of the new derivatives in the current work is 
encouraging in this respect, and is, indeed, reflected in the increased photoantimicrobial 
efficacies reported here. 
The toxicology of new drug candidates is, of course, paramount in establishing a route 
forward towards clinical trialling.  One of the better candidates from the current work is 
currently beginning initial small scale testing in this respect and this work will be reported at 
a later date. 
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